BIOLARGO director receives 92,593-share option grant
BIOLARGO, INC. director Jack B. Strommen received an option grant as compensation for board service.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
BIOLARGO, INC. director Jack B. Strommen received an option grant as compensation for board service. He was awarded an Option to Purchase Common Stock covering 92,593 shares at an exercise price of $0.162 per share, with no cash paid for the grant itself.
The option was issued in lieu of $15,000 in director fees for the most recently completed quarter under the company’s 2024 Equity Incentive Plan. Following this grant, Strommen directly holds derivative securities representing 2,452,103 underlying shares, and this option is scheduled to expire on March 31, 2036.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Option to Purchase Common Stock | 92,593 | $0.00 | $0.00 |
Footnotes (1)
- F1. This Option was issued to Reporting Person as payment for $15,000 in fees due to Reporting Person by Issuer in exchange for services on its board of directors for the most recently completed quarterly period, pursuant to the Issuer's 2024 Equity Incentive Plan. The number of shares in the Option is equal to the amount of fees due divided by the exercise price of the Option.
Key Figures
Key Terms
Option to Purchase Common Stock financial
exercise price financial
Equity Incentive Plan financial
board of directors financial
AI-generated analysis. How Rhea-AI works. Not financial advice.